Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.52 |
| ▸ | LONP1 | P36776 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.44 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.44 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.44 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.44 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410890 | 1.00 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL3213475 | 1.00 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL1013600 | 1.00 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL2408343 | 1.00 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL464244 | 1.00 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL464151 | 0.99 | ABCG2 (0.53) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL12011280 | 0.92 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL12331437 | 0.92 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL13092003 | 0.92 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL12404543 | 0.91 | ABCG2 (0.53) | ABCG2CTSBELANECTSLCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103483420-B | A kind of Telaprevir intermediate in B crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-16 | — | — | CN | claimed |
| CN-103483419-B | A kind of Telaprevir intermediate C crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-09 | — | — | CN | claimed |
| CN-103497234-B | Telaprevir intermediate crystal form-A and synthesis method thereof | SUZHOU UUGENE BIOPHARMA CO LTD | 2015-07-08 | — | — | CN | claimed |
| WO-2014083582-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1S,3AR,6AS)-2-[(2S)-2-({(2S)-2-CYCLOHEXYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]ACETYL}AMINO)-3,3-DIMETHYLBUTANOYL]-N-[(3S)-1-(CYCLOPROPYLAMINO)-1,2-DIOXOHEXAN-3-YL]-3,3A,4,5,6,6A-HEXAHYDRO-1H-CYCLOPENTA[C] PYRROLE-1-CARBOXAMIDE AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2014-06-05 | — | — | WO | claimed |
| CN-103497234-A | Telaprevir intermediate crystal form-A and synthesis method thereof | SUZHOU UUGENE BIOPHARMA CO LTD | 2014-01-08 | — | — | CN | claimed |
| CN-103483419-A | Telaprevir intermediate in crystal form C, and synthesis method thereof | SUZHOU UUGENE BIOPHARMA CO LTD | 2014-01-01 | — | — | CN | claimed |
| CN-103483420-A | Telaprevir intermediate in B crystal form and synthesis method thereof | SUZHOU UUGENE BIOPHARMA CO LTD | 2014-01-01 | — | — | CN | claimed |
| CN-103342736-B | A kind of synthetic method of VX-960 | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-103342736-B | A kind of synthetic method of VX-960 | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-103483420-B | A kind of Telaprevir intermediate in B crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-16 | — | — | CN | disclosed |
| CN-103483420-B | A kind of Telaprevir intermediate in B crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-16 | — | — | CN | disclosed |
| CN-103483419-B | A kind of Telaprevir intermediate C crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-09 | — | — | CN | disclosed |
| CN-103483419-B | A kind of Telaprevir intermediate C crystal form and synthetic method thereof | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2015-09-09 | — | — | CN | disclosed |
| US-20120330015-A1 | PROCESS FOR THE PREPARATION OF alpha-ACYLOXY beta-FORMAMIDO AMIDES | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2012-12-27 | — | — | US | disclosed |
| WO-2011103932-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011103933-A1 | PROCESS FOR THE PREPARATION OF α-ACYLOXY β-FORMAMIDO AMIDES | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2011-09-01 | — | — | WO | disclosed |
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, PEPD, PREP | ABCG2 515/4885CTSB 38/4885ELANE 108/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABCG2 211/4885CTSB 1766/4885ELANE 169/4885 |
| US-20120330015-A1 | PROCESS FOR THE PREPARATION OF alpha-ACYLOXY beta-FORMAMIDO AMIDES | ASPH, NGLY1, C9 | ABCG2 3443/4885CTSB 836/4885ELANE 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.